Navigation Links
Genetic approach provides new insight into trastuzumab resistance in breast cancer
Date:10/15/2007

A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab (Herceptin). The research, published by Cell Press in the October issue of the journal Cancer Cell, identifies markers that may help to identify patients who are unlikely to respond to trastuzumab treatment and provides a potential strategy for treating these patients.

Trastuzumab is an antibody used as a therapy for patients whose breast cancers produce excess amounts of the protein HER2. However, almost half of these breast cancer patients are nonresponsive to trastuzumab therapy or become resistant during treatment. To better understand the antitumor activity of trastuzumab, Dr. Rene Bernards from The Netherlands Cancer Institute and his colleagues used a large-scale genome-wide RNA interference screen to search for genes involved in trastuzumab resistance in breast cancer.

The researchers identified only the tumor suppressor PTEN as a modulator of trastuzumab sensitivity in a breast cancer cell line. Earlier findings had associated PTEN with resistance to trastuzumab-based therapy, and loss of PTEN is known to result in hyperactivation of the PI3K pathway. Abnormal activation of this cell survival signaling pathway has been identified in many primary breast cancers. Hyperactivation of the PI3K pathway also can be caused by activating mutations of the PIK3CA gene.

This finding, along with the high frequency of PIK3CA activating mutations in breast cancer, led us to investigate whether PI3K pathway activity, as assessed by cancer-associated activating mutations (of PIK3CA) or altered levels of PTEN, was able to predict trastuzumab resistance in the clinic, explains Dr. Bernards. This combined analysis identified twice as many patients at increased risk for disease progression as would analyzing PTEN alone and proved to be statistically significant as a biomarker for prognosis after trastuzumab therapy, indicating that assessment of PTEN expression together with PIK3CA mutation is required for optimal prediction of disease progression after trastuzumab therapy for breast cancer.

Importantly, this study also illustrates the power of in vitro RNAi screens combined with confirmation on patient samples to identify biomarkers useful for predicting treatment response in the clinic, says Dr. Bernards. It is too early to use these biomarkers; further validation studies are required before they can be used in the clinic. Nevertheless, it is likely that these findings will lead to a better understanding of resistance mechanisms and how to circumvent them as well as more reliable identification of the most effective treatment for individual patients.


'/>"/>
Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Genetic Dentistry: Your Dentist may be able to grow you a new set of Teeth.
2. Crowning glory of 2000!!! Cracking of the genetic code is top of tops
3. Genetic influence in menopause
4. Genetic differences found between Male and Female brains
5. Genetic Breakthrough in Common Eye Problem
6. Inflammatory bowel disease linked to genetic abnormality
7. Genetic Code Of C.difficile Cracked
8. Genetics and cholesterol levels
9. Genetics helps in attacking cancer
10. DNA biochip for genetic screening
11. Genetic disorder related with sleep patterns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and beyond ... strives to better communities around the world by offering the Gensuite team and ... opportunity for team members to become involved in a cause that is bigger ...
(Date:1/15/2017)... Rosa, CA (PRWEB) , ... January 15, 2017 ... ... nominate their choice of best physicians in eight Bay Area counties for 2017. ... by the healthcare research company managing the award process. Results were announced the ...
(Date:1/14/2017)... Minneapolis, MN (PRWEB) , ... January 14, 2017 ... ... to present the distinctions among their expanding line of activated charcoal products. With ... emphasizes the importance of categorizing their products according to how they cater to ...
(Date:1/13/2017)... ... 2017 , ... People with type 2 diabetes know to ... as checking the nutrition label on foods for grams of sugar. But carbohydrates ... proteins can influence — either positively or negatively — insulin secretion and glucose ...
(Date:1/13/2017)... ... January 13, 2017 , ... With the increasing public ... of providing additional organic alternatives for customers who have grown more conscious about ... line of all-natural activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... SAN FRANCISCO, Calif. , Jan. 16, 2017 /PRNewswire/ ... that on January 3, 2017 and January 16, 2017 ... the grant of inducement stock options to purchase an ... new employees. These awards were granted pursuant to the ... inducement material to the new employees entering into employment ...
(Date:1/16/2017)... Colo. , Jan. 16, 2017 CBDRx, ... donate large amounts of phyto-nutrient rich hemp extract to ... the donation of their proprietary hemp extract to Veteran,s ... CBDRx the best hemp company in the world and ... best, most nutritious, full spectrum phyto-nutrient rich hemp extract ...
(Date:1/15/2017)... -- Le conseil d,administration de SurgaColl Technologies Ltd., ... la régénération de tissus humains, annonce la nomination de ... effet immédiat. ... Bill est un dirigeant expérimenté à l,international dans l,industrie ... générale et de direction au sein de sociétés internationales spécialisées ...
Breaking Medicine Technology: